Effect of Exenatide on Glucose Homeostasis Determinants in Type 2 Diabetes

NCT00948168 on ClinicalTrials.gov · last registry update 2009-07-31

A small phase 4 — 34 participants, against a typical 75. The sponsor logged completion for July 2009. Primary outcome, as filed: Improvement in HbA1c. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Sponsor type: Other
Enrollment: 34
Started: 2008-07
Primary completion: 2009-07 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Improvement in HbA1c

Conditions studied

Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.